一种针对中度至重度COPD患者的新型向性肺缩多极射频除系统:一个转化研究
Rui Xu1, Liangyuan Li1, Yongchun Shen1
1Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, Chengdu, Sichuan Province, 610041, China.
Respiratory research
|January 12, 2026
概括
一种针对有针对性的肺缩 (TLD) 的新型多极射频除系统显示在治疗慢性阻塞性肺病 (COPD) 中具有可行性. 这种创新的TLD方法有可能改善COPD患者的肺功能和安全性.
科学领域:
- 肺部医学 肺部医学
- 干预性肺病学 干预性肺病学
- 医疗器械开发 医疗器械开发
背景情况:
- 破坏副交感肺神经可以改善COPD患者的肺功能.
- 目前的有针对性的肺排气系统 (TLD) 需要进行结构性改进,以提高安全性和更广泛的应用.
- 为COPD的TLD提出了一种新型的多极射频 (RF) 除系统.
研究的目的:
- 开发和评估一种新的多极射频消化系统,用于COPD的TLD.
- 评估这个新的TLD系统的可行性,安全性和初步有效性.
主要方法:
- 临床前研究包括体外 (猪模型) 和体内 (狗,羊) 实验.
- 一项首次在人身上进行的研究招募了中度至重度COPD的患者 (FEV1/FVC<0.70;预测FEV1的20%-60%).
- 安全终点侧重于不良事件;疗效终点包括程序成功,肺功能 (FEV1),运动能力和生活质量.
主要成果:
- 实验室试验证实了在冰冷盐水灌后的剥离范围 (6-8毫米).
- 在体内研究表明TLD可行性在狗和呼吸道上皮质还原在绵羊超过一年.
- 第一次在人体上的研究显示了良好的耐受性,100%的仪器成功,88.9%的技术成功,并在6个月后改善FEV1和生活质量,并在12个月后恢复到基线.
结论:
- 新的多极射频TLD系统可用于治疗COPD患者.
- 需要在更大的患者队伍中进一步验证,以确认安全性和临床疗效.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433